(b) centrifuging the mixture to obtain the separation of phases;

(c) recovering the supernatant and measuring the drug concentration.

2. (Amended) Method according claim 1 wherein the concentration of the aqueous zinc sulfate solution ranges from 0.1 M to 5.0 M.

3. (Amended) Method according claim 2 wherein the concentration of the aqueous zinc sulfate solution ranges from 0.2 M to 1.0 M.

10. (Amended) Method according claim 1 wherein the drug to be analyzed is selected from the group of antimonials, itraconazole, proteinase inhibitors and reverse transcriptase inhibitors.

11. (Amended) Method of monitoring patient compliance and bioavailability of rifampicin contained in body fluids comprising the following steps:

(a) mixing and shaking mechanically the body fluid with aqueous zinc sulfate solution, an organic solvent selected from the group consisting of acetonitrile / 2-propanol (1:1), benzene, toluene, dichloromethane, chloroform or mixtures thereof and optionally an antioxidizing agent to precipitate proteins and strip off bound drug;

(b) centrifuging the mixture to obtain the separation of phases;

(c) recovering the supernatant and measuring the drug concentration by using a colorimetric assay or a High-Performance Liquid Chromatography method.